Table 1.

Baseline characteristics for healthy controls and participants with ALS.

Baseline characteristic	ALS ($n=12$)	Controls ($n=9$)
	%(n)/ $\mu$($\sigma$)	%(n)/ $\mu$($\sigma$)
Age at screening (yrs)	56.8 (10.3)	53.2 (11.1)
Genetic abnormality	unknown (11)	n/a
	C9orf72 positive (1)
Male	75% (9)	55% (5)
Caucasian	100% (12)	100% (9)
Symptom onset to diagnosis (months)	10.3 (7.0)	n/a
Symptom onset to scan (months)	30.3 (23.4)	n/a
Limb onset	67% (8)	n/a
Baseline SVC (% predicted)	93.4% (22.2%)	n/a
ALSFRS-R at baseline	38.1 (4.8)	n/a
Estimated ALSFRS-R slope pre-baseline ((48 – baseline ALSFRS-R)/ disease duration) (points/month)	0.46 (0.35)	n/a
Revised El Escorial criteria	definite (5)	n/a
	probable (3)
	probable lab supported (1)
	possible (3)
Riluzole use	75% (9)	n/a